Earnings Call · Q1 FY2023·2023-05-14

Q1 23EPS +28.27%·Rev n/aQ4 22EPS -9.52%·Rev n/aQ3 22EPS +18.45%·Rev n/aQ2 22EPS +25.00%·Rev n/a⚠ consensus missing

MiNK Therapeutics, Inc. INKT

Zack Armen — Head of Investor Relations

Jennifer Buell — Chief Executive Officer

Marc Van Dijk — Chief Medical Officer

Christine Klaskin — Chief Financial Officer

+7.3%1d on move date+7.5% vs SPY3d+11.9%5d+19.2%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INKT calls or request research access.

More INKT calls Browse calls Request research access